Ozempic vs Wegovy vs Generic Semaglutide: What's the Difference?

Across Canada, interest in GLP-1 treatments continues to grow. In fact, in 2025 searches for “weight loss medication side effects” increased nationally by 437%. And, with more types of treatment now available in Canada, there’s also increasing interest in the options available.

In this guide, we’ll explore the difference between three GLP-1 medications prescribed in Canada: Ozempic, Wegovy and generic semaglutide. Although each contains the same active ingredient (semaglutide), none of these are quite the same treatment: each is authorized for different uses, prescribed under different guidance, dosage and pricing.

We’ll explain how they compare, what treatment involves and whether it may be right for you. Remember that any final treatment decision rests with a registered clinician, and is subject to eligibility.

Article summary:

• Ozempic, Wegovy and generic semaglutide all contain the same active ingredient, semaglutide, but they're authorized for different uses: type 2 diabetes or weight management.
• Each is given as a once-weekly injection, starting at a low dose that increases gradually. This helps your body adjust and keeps side effects manageable.
• The right option for you depends on your eligibility, health and your goals. That's why a registered clinician checks what's safe and suitable before you start.

What is semaglutide?

Semaglutide is a synthetic version of a natural hormone called GLP-1 (glucagon-like peptide-1), which helps regulate blood sugar levels and appetite. [1]

How semaglutide works in your body

Semaglutide works in a few ways. It:

• Slows down digestion, so you feel full for longer.
• Reduces your appetite and reduces “food noise”, so you eat less.
• Helps your body release insulin after you eat, which supports steadier blood sugar levels.
• May help lower blood pressure and support your cardiovascular health. [2, 3]

Semaglutide works best alongside positive lifestyle changes, like a balanced diet and regular movement. Together, these may lead to long-term health improvements. [4]

Ozempic, Wegovy and generic semaglutide: at a glance

Ozempic, Wegovy and generic semaglutide all contain the same active ingredient: semaglutide. But Health Canada has authorized each one for a different use, and each comes in different doses. [5]

Ozempic is authorized to help manage type 2 diabetes and blood sugar levels. It's given at lower doses, up to 1mg once weekly. It's not authorized for weight loss on its own, though some people may lose weight while taking it. [6]

It may also help lower the risk of serious cardiovascular disease, like heart attack and stroke, in adults with type 2 diabetes who already have heart disease. [6]

Wegovy is authorized for chronic weight management. It's given at higher doses, up to 2.4mg once weekly, and its use for weight loss is backed by dedicated clinical trials. [5, 4]

Generic semaglutide is a "generic" (non-branded) medication which is authorized by Health Canada for chronic weight management. It contains the same active ingredient (semaglutide), and is medically equivalent to its branded counterparts.

Whether you choose a brand name medication or a generic medication, both must meet the same Health Canada standards for safety and quality. And generic drugs like generic semaglutide must go through rigorous testing before approval. Health Canada reviews the chemical processes and manufacturing standards behind every generic drug, along with the drug supply chain, to check it works the same way as the original. [7] And, like the branded treatments, it's prescription-only, requires a clinical assessment and is dosed under medical supervision.

Both branded and generic options have trade-offs around cost, availability and suitability, which a clinician will assess alongside your health to make sure your treatment is right for you.

Ozempic, Wegovy and generic semaglutide: the cost

The price of weight management treatment depends on the medication, the dose and where you get it.

Generic medications (like generic semaglutide) are usually more affordable than brand name medications (like Wegovy), because manufacturers of generics don't need to recover the same research and development costs. Patent laws give the pharmaceutical company that first develops a medication, like Novo Nordisk (the company behind Ozempic and Wegovy), a period of exclusive rights before other manufacturers can create a generic version. Once the patent protection on the original drug ends, other manufacturers may begin producing generic versions of the same drug. This is why generic semaglutide is now available in Canada.

Where available, generic semaglutide may offer a more affordable route to treatment than Wegovy. [7]

Ozempic, Wegovy and generic semaglutide: clinical results

Both Wegovy and generic semaglutide may support weight loss. Because they share the same active ingredient, the clinical data for semaglutide 2.4mg applies to both. [4, 7]

In a major clinical trial called STEP 1, adults with overweight or obesity took semaglutide 2.4mg once weekly, alongside diet and exercise changes, for 68 weeks. On average, they lost 14.9% of their body weight, compared with around 2.4% for people taking a placebo. [4] However, individual results may vary.

Ozempic has been shown to effectively manage blood sugar levels in those with type 2 diabetes. [8] Weight loss with Ozempic, taken for type 2 diabetes, tends to be smaller. That's because it's usually given at a lower dose, and any weight loss is a secondary effect rather than the main goal of treatment. [6]

Obesity and type 2 diabetes are long-term conditions, so weight regain or rising blood sugar levels are common if you stop treatment. [4] Treatment for weight management is often used for a set period. Your clinician monitors your progress, adjusts your dose and advises how long to continue.

Everyone responds differently. If you're eligible for treatment, a clinician will help you decide which treatment may be right for you.

How do you take them?

Ozempic is given once a week by injection. You typically start at 0.25 mg and increase gradually. [6]

Wegovy is also given once a week, as an injection under your skin. Most people start at a low dose of 0.25 mg. Your clinician increases this gradually, based on your weight loss, side effects and overall appetite, to a maximum of 2.4mg per week. [5] Some people only ever need a small dose and some need higher doses. Our approach is personalized, balancing results, safety and budget.

Generic semaglutide is also given once a week by injection, using an injection pen. It follows the same gradual dosing approach. [7]

Starting low and increasing your dose slowly is called “titration”. It gives your body time to adjust and helps to manage side effects.

Side effects and safety

Side effects can happen with any semaglutide treatment, since they share the same active ingredient.

Most side effects are mild and settle down as your body adjusts.

The most common side effects include:

• Nausea
• Diarrhea
• Constipation
• Vomiting [6, 9]

Less common but more serious side effects may include:

• Inflammation of the pancreas, called pancreatitis
• Gallbladder problems
• Kidney problems, often linked to dehydration from vomiting or diarrhea. This needs extra care if you already have chronic kidney disease.
• Low blood sugar, especially if you also take insulin or other diabetes medication. [6, 9]

Semaglutide shouldn't be used if you or a close family member has had a type of thyroid cancer called medullary thyroid cancer, or a rare inherited condition called multiple endocrine neoplasia type 2. It also shouldn't be used during pregnancy or while breastfeeding. [6, 9]

This isn't a complete list. Please refer to your Patient Medication Information (PMI) for further information about safety and side effects.

Who can use Ozempic, Wegovy or generic semaglutide?

Ozempic is generally prescribed for adults with type 2 diabetes that isn't well-controlled. [6]

Wegovy is generally considered for adults whose weight meets its approved use, as assessed by a clinician.

Generic semaglutide may be considered as an alternative to Wegovy for eligible adults, as assessed by a clinician.

Treatment isn't right for everyone, and not everyone will qualify. A registered clinician looks at your medical history, current medications and overall health. This helps them decide if treatment is safe and suitable for you.

Switching between treatments

Some people switch between treatments, with their clinician's guidance. This may be due to supply, cost, side effects, how well the treatment is working or a change in diagnosis. And it may include moving between a brand name medication and generic medication.

Any switch should happen under medical supervision, with your clinician monitoring your dose, side effects and results.

Next steps

So, Wegovy vs Ozempic vs generic semaglutide: which is right for you? They may all contain the same active ingredient, but they differ in their approved use, dose, availability and cost.

Wegovy is authorized for weight management, and it's been studied specifically for that. Ozempic is authorized for type 2 diabetes, with weight loss as a secondary effect. Generic semaglutide offers the same active ingredient as Wegovy, often at a lower cost.

The right option for you depends on your health, your goals and a clinician's assessment.

Find out which treatment may be suitable for you with MedExpress.

A note from the experts: This article is for general information and should not be taken as medical advice, diagnosis or treatment. We make sure everything we publish is reviewed by clinical experts and updated regularly, but it may not always reflect the most recent health guidance. Always speak to a healthcare professional about any health concerns.

Prescriptions are discretionary and subject to a clinical assessment by a licensed healthcare practitioner. Prescriptions are dispensed by an independent pharmacy. Not all patients will qualify. Results vary. Services are not insured by any province’s public health insurance.

References

1. Fisher J. How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond - Harvard Health [Internet]. Harvard Health. 2025 [cited 2026 July 15]. Available from: https://www.health.harvard.edu/healthy-aging-and-longevity/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond

2. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism [Internet]. 2017 May 5 [cited 2026 July 15];19(9):1242–51. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573908/

3. MacIsaac RJ. Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. Future cardiology [Internet]. 2025 Mar [cited 2026 July 15];1–21. Available from: https://pubmed.ncbi.nlm.nih.gov/40458885/

4. Wilding JPH, Batterham RL, Calanna S. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine [Internet]. 2021 Feb 10 [cited 2026 July 15];384(11):989–1002. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

5. Regulatory Decision Summary for Wegovy - Drug and Health Products Portal [Internet]. Hpfb-dgpsa.ca. 2021 [cited 2026 July 15]. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00896

6. Novo Nordisk Canada Inc. Product monograph: Ozempic (semaglutide injection) [Internet]. Mississauga (ON): Novo Nordisk Canada Inc; 2025 [cited 2026 Jul 15]. Available from: https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/ozempic/product-monograph/ozempic-pm-en-21-august-2025.pdf

7. Health Canada. Canada approves first generic semaglutide for weight loss [news release]. Ottawa (ON): Health Canada; 2026 Jun 29 [cited 2026 Jul 15]. Available from: https://www.canada.ca/en/health-canada/news/2026/06/canada-approves-first-generic-semaglutide-for-weight-loss.html

8. Berra C, Maria Chiara Rossi, Mirani M, Daniela Ceccarelli Ceccarelli, Romano C, Sassi L, et al. Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01). Frontiers in Endocrinology. 2023 Jan 18;13.

9. Wegovy ® (semaglutide injection) Product Monograph Unclassified / Non classifié Product Monograph Including Patient Medication Information PR WEGOVY ® semaglutide injection Solution for Subcutaneous Injection in a pre-filled pen Produced by recombinant DNA technology in Saccharomyces cerevisiae [Internet]. [cited 2026 July 16]. Available from: https://pdf.hres.ca/dpd_pm/00082777.PDF